Biotech

All Articles

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our summary of substantial leadership hirings, shootings...

Lykos will definitely inquire FDA to reevaluate its selection adhering to rejection of MDMA treatment for trauma

.Adhering to a bad showing for Lykos Therapies' MDMA candidate for post-traumatic stress disorder at...

AN 2 one-halfs head count, quits period 3 trial after data let down

.AN2 Therapeutics is reviewing its own service in response to dull midphase data, promising to lay o...

Merck spends $700M for bispecific, spying autoimmune opening as well as chance to challenge Amgen in cancer

.Merck &amp Co. is actually paying $700 million in advance to test Amgen in a blood stream cancer ma...

Gilead pays for J&ampJ $320M to exit licensing offer for seladelpar

.Along With Gilead Sciences about to an FDA selection for its own liver ailment drug seladelpar, the...

' All hands on deck' at Lilly as peers target obesity market

.Chief executive officer David Ricks can view the firms setting up camping tents at basecamp behind ...

Entero giving up personnel, vacating workplace and also stopping R&ampD

.Mattress Liquidators has actually transformed Entero Therapeutics white as a slab. The lender purch...

Exelixis goes down ADC after deciding it's no suit for Tivdak

.Exelixis is actually quiting on its own cells aspect (TF)- targeting antibody-drug conjugate after ...

Relay dislikes SHP2 prevention after Genentech leaves behind

.Three weeks after Roche's Genentech unit bowed out an SHP2 inhibitor treaty, Relay Rehab has actual...

Stoke's Dravet disorder med released of predisposed scientific grip

.Stoke Therapeutics' Dravet syndrome medicine has been actually freed from a partial hold, getting r...